The global leaderboard of wealth: $1.2 Quadrillion of Assets ranked by Market Cap
In-depth research + analysis available with Pro ($3.99/mo) or Pro Plus ($9.99/mo). Everything else on this page is free.
Article
Article
Article
Article
The XRP ETFs haven't been in the red weekly for nearly two months. The HYPE ETFs haven't seen a single red week since their debut.
Bitcoin dropped below $60,000 by mid-June after a punishing start to the month, but the figure drawing the most attention across trading desks is the June 26 Bitcoin options expiry, with over $10 billion of contracts set to expire and rough
A quiet legal maneuver to seize title to more than $200 billion in dormant Bitcoin, including Satoshi Nakamoto's, has encountered a fundamental flaw. A lost Bitcoin wallet lawsuit in New York now faces direct on-chain evidence that supposed
Three laden oil supertankers, with a combined transport capacity of 6 million barrels, emitted signals as they were sailing through the channel on Saturday via a route that hugs Oman’s coast.
The U.S. cattle herd is at its lowest point since the 1950s. Trump's USMCA threat could make the beef price crisis permanent.
Over 550 California workers have developed an incurable lung disease from fabricating engineered stone for Home Depot, Lowe's, and Costco kitchens.
It's not laziness — NSF-funded research on 4,000 consumers finds that something kicks in precisely at the moment of disposal.
Ukrainian forces have repeatedly targeted fuel supplies to Crimea in recent weeks, triggering the worst energy crisis in the region since it was illegally annexed by Russia in 2014.
Absci Corporation (ABSI) is making waves in the biopharmaceutical sector by leveraging artificial intelligence to accelerate drug discovery. As it progresses through human trials with its lead program, ABS-201, investor interest is surging. This article explores the company's potential, the implications of its AI-driven approach, and the broader market context. ## BODY: ### Introduction: The Intersection of AI and Biopharmaceuticals In recent years, the biopharmaceutical industry has witnesse